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Healthcare workers who prepare or administer cytotoxic agents run the risk of exposure, and the risks for health are real 
even at doses lower than those applied in cancer patients, because, in theory, no dose is safe. The most common and 
problematic route of exposure is through the skin, especially as work surfaces can remain contaminated even after cleaning. 
This pilot study aimed to demonstrate the importance of having an effective surface decontamination protocol by 
determining surface contamination with cyclophosphamide, 5-fluorouracil, and paclitaxel as the most common cytotoxic 
drugs in an oncology day service. Samples were collected before and after drug handling and analysed with high performance 
liquid chromatography with diode array detection (HPLC-DAD). Of the 29 samples collected before drug handling 23 
were contaminated, five of which with more than one drug. Of the 30 samples collected after drug handling 25 were 
contaminated, eight of which with more than one drug. The two time points did not significantly differ, which evidences 
a widespread contamination and ineffective cleaning. This calls for revising the cleaning protocol and handling procedure 
to place contamination under control as much as possible.
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Cytotoxic drugs have been recognised as hazardous to 
healthcare professionals such as medical doctors, oncology 
nurses, pharmacists, and other staff, including maintenance, 
since the late 1970s (1). The European Agency for Safety 
and Health at Work (EU-OSHA) (2) and the European 
Commission Directorate-General for Employment, Social 
Affairs, and Inclusion (3) are well aware of the issue, but 
the legislation of the member states still has not been 
harmonised in terms of risk prevention in the healthcare 
sector (4). The EU legislation, however, does require from 
employers to provide a monitoring programme for 
carcinogenic compounds, which includes most of the 
cytotoxic drugs (4).
Essentially, their mechanism of action comes down to 
inhibiting tumour growth and cell division by interfering 
with the cell genetic material. However, the most common 
cytotoxic drugs are not specific enough to target tumour 
cells alone, but they also affect healthy cells of the exposed 
individuals (5-11). This can lead to genotoxic effects that 
can result in gene alterations and neoplasms in healthy 
population or secondary tumours in treated cancer patients 
(7, 9, 12).
Even exposure to doses lower than those received by 
cancer patients can produce adverse health effects, 
especially in chronically exposed healthcare workers (13-
16). There have been reports of reproductive toxicity that 
can result in miscarriage, temporary or permanent infertility, 
preterm births, congenital malformations, and learning 
disabilities in the children of the exposed individuals (17, 
18). In addition, long-term occupational exposure has been 
associated with increased risk of hair loss, infections 
(attributed to lower white blood cell count and 
immunosuppression), organ toxicity (e.g. liver, kidney, lung, 
and cardiac toxicity), myelotoxicity, mucosal ulcers, fatigue, 
bleeding, and headaches (19). Furthermore, occupationally 
exposed individuals have a higher incidence of DNA 
damage, chromosomal abnormalities, and cancer consistent 
with the inherent carcinogenic properties of these drugs 
(15, 20, 21).
Exposure can occur at every stage of the cytotoxic drug 
lifecycle: from production and distribution to its application 
in hospital or home care settings and its disposal as waste. 
The risk of exposure is not limited to healthcare workers 
who prepare (pharmacists and pharmacy technicians) or 
administer (nurses) cytotoxic agents. Anyone in touch with 
contaminated air or objects or even patient excreta is at risk 
(12, 22-26). One Dutch study (25) identified home care, 
nursing homes, and laundry facilities as non-hospital 
occupational settings with higher exposure, which were all 
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related to the care of cancer patients. Clearly, a large number 
of workers can be exposed to cytotoxic agents in three ways: 
through inhalation of aerosolised drugs; through direct skin 
contact, and rarely through ingestion from contaminated 
hands and gloves (27). However, thanks to advanced 
protection technology available at the workplaces, such as 
biological safety cabinets, the most common and 
problematic route of exposure is skin (4, 28).
Yet, even with improvements in safe handling practices 
exposure to cytotoxic drugs is still a threat. Some studies 
reported traces of several cytotoxic drugs on work surfaces 
serving for receiving, storing, preparing, and validating 
preparations in hospital pharmacies (29-33) and even on 
surfaces in administration areas (33, 34). Some reported 
cytotoxic drugs in biological samples (blood and urine) 
from healthcare workers (19, 35-37) and some reported 
contamination of work surfaces even after their cleaning 
(4, 37-40).
The aim of this pilot study was therefore to establish 
working surface contamination with cytotoxic drugs in an 
outpatient oncology setting and see how effective the 
adopted standard decontamination procedures are.
MATERIALS AND METHODS
Our study focused on the drug preparation unit and the 
drug administration unit of an oncology day service (ODS), 
which treated 375 patients (over 3145 visits) in 2015. It 
also included the toilets used by patients and their 
accompanying family members, who also run the risk of 
exposure (Figure 1).
Before sampling began, we gathered information about 
the number of chemotherapies prepared, most common 
drugs used, application methods, and post-treatment 
cleaning procedures. We also asked the staff to carry on 
cleaning as usual to avoid bias. For sampling we chose a 
day regarded as »normal« by the staff in terms of the number 
of treatments. Samples from the working and other surfaces 
were taken with wipes (24).
The preparation unit had four pharmacists, three 
pharmacy technicians, and four assistants. It did not use a 
closed-system drug transfer device and had only two 
biosafety cabinets to prepare the cytotoxic drugs, but only 
used one at a time. The cytotoxic drugs in this unit were 
handled as follows: pharmacists would send the drugs to 
pharmacy technicians to prepare them in one of the 
biosafety cabinets and then check the preparations. Then 
the assistants would carry the preparations in a specific 
container similar to a biohazard box to the drug administration 
unit (Figure 1).
The administration unit had thirteen infusion chairs and 
three beds (plus two if needed) attended by 14 nurses and 
seven assistants. There was also a reception desk for patient 
registration on visits.
The drug preparation and administration surfaces are 
cleaned at the end of the working day. The toilet is cleaned 
several times a day and more thoroughly at the end of the 
day. The cleaning products used were the same as in other 
hospital facilities For the surfaces the staff used a product 
containing sodium tripolyphosphate (2.5-10 %), sulphonic 
acid (<2.5 %), sodium lauryl ether sulphate (2.5-10 %), 
propan-2-ol (2.5-10 %), and a small percentage of alcohol. 
For patient toilet they used a product with sodium 
hypochlorite (<5 %).
Sampling
The choice of surfaces or objects to be wiped for 
samples was based on the observed everyday activities at 
the ODS and included surfaces and objects likely to be 
contaminated with cytotoxic drugs either through work or 
other routine behaviour (33).
Each spot was sampled twice: in the morning before 
drug handling started and three hours after it started. In total 
we collected 59 samples. Of the 29 morning samples, 12 
were taken from the preparation unit, 12 from the 
administration unit, and five from the patient toilet. Three 
hours into the drug handling, we took 30 more samples: 12 
from the preparation unit, 13 from the administration unit, 
and five from the toilet.
Samples were taken with a 100 cm2 Kimtech Science 
wipe (Kimberly-Clark Professional, Roswell, GA, USA) 
soaked in ethyl-acetate and fastened to a stainless steel 
frame (100 cm2), as described elsewhere (33), except for 
door handles, computer mice, and telephones, where we 
could not use the stainless frame for obvious reasons. The 
wipes were then placed in Petri dishes, sealed with Parafilm 
M® (Bemis, Neenah, WI, USA), stored at 2–8 °C for 
transport to the laboratory in Lisbon (3 h), and then frozen 
at -20 °C up to two months until analysis.
The frame was cleaned between each sampling, and a 
new pair of gloves was used for each new wipe. All wipe 
samples were collected by the same person to ensure reliable 
and similar sampling. Blank wipes were used to check that 
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Figure 1 The three units sampled in the ODS
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no contamination occurred during sampling and 
transportation to the laboratory.
Sample analysis
The samples were analysed for cyclophosphamide (CP), 
5-fluorouracil (5-FU), and paclitaxel (PTX) as the most 
commonly and abundantly used drugs in our ODS and in 
most of the oncology settings. Testing for all cytotoxic drugs 
would be too cost-ineffective (31, 32, 40-44).
The wipes were placed in 15-mL capped tubes with 
10 mL of mobile phase (see below) for extraction in a roll 
homogeniser for 10 minutes.
The extracts were then forced through a 0.2 µm filter 
and injected in a high-performance liquid chromatographer 
with a diode array detector (HPLC-DAD) for separation 
and quantification with a Thermo Unicam Surveyor 
(Thermo ScientificTM, San José, CA, USA). To do that we 
used the C18 Hypersil-GOLD® (Thermo ScientificTM) 
1 5 × 5 × 4 . 6 ,  a  r e s p e c t i v e  g u a r d  c o l u m n ,  a n d 
acetonitrile:methanol:water (19:13:68) as mobile phase. 
The flow rate was 0.8 mL min−1. All the HPLC-grade 
solvents used were purchased from VWR International 
(Radnor, PA, USA). CP, 5-FU, and PTX for calibration were 
purchased from Merck KGaA (Darmstadt, Germany). 
Calibration curves were obtained after their extraction from 
spiked wipes. Each sample was injected in triplicate. 
Chromatograms were integrated with the XcaliburTM 2.0 
software (Thermo ScientificTM).
Method validation
Validation followed the US Food and Drug 
Administration regulatory guidelines for analytical 
procedures (57). Table 1 shows the results of method 
validation, including the limit of detection (LOD) and limit 
of quantification (LOQ), which were within the range for 
this method (66-68). A sample was considered positive for 
a particular drug if the value was above LOD.
All calibration curves with a correlation coefficient (R2) 
greater than 0.990 for the three drugs were linear over the 
range. The LOD and LOQ correspond to the mean of five 
calibration curves.
Tables 2, 3, and 4 show the intra- and inter-day accuracy 
and precision parameters at six calibration levels. Table 5 
summarises recoveries of 5-FU, CP, and PTX.
Their retention time was about 3.9, 5.8, and 18.4 
minutes, respectively. Their typical chromatograms were 
well resolved, which indicates that the assay was selective 
(Figure 2).
Statistical analysis
Normality of distribution was tested with the Shapiro-
Wilk test. Prevalence of contamination before and after 
drug handling was compared with the frequency analysis. 
To compare drug concentrations at both time points (before 
and after drug handling started) between the three locations 
(drug preparation unit, drug administration unit, and patient 
toilet) we used the Kruskal-Wallis test. Kruskal-Wallis 
multiple comparison was also used for significantly 
different results. To compare 5-FU, CP, and PTX 
concentrations between the two time points we used the 
Wilcoxon test. The level of significance was set at a 5 %.
RESULTS
Table 6 shows the distribution of positive samples with 
quantifiable drugs (>LOQ) by sampling time. Of the 29 
morning samples 21 were contaminated: seven in the 
preparation unit, 10 in the drug administration unit, and 
four in patient toilet (Table 7). Of these, three were 
contaminated with more than one drug:, two in the drug 
administration unit, and one in the patient toilet.
Of the 30 samples collected three hours into the drug 
handling, 24 were positive, 19 of which from the drug 
preparation and administration units and 5 from the patient 
toilet (Table 8). Of these, five were contaminated with more 
than one drug: four in the preparation unit, and one in the 
drug administration unit.
Table 9 shows total contamination of each unit by drug.
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Figure 2 Typical chromatogram of a wipe spiked with the 
drugs under study A: all three drugs; B, C, and D: 
absorption spectra
Table 1 Method validation for each cytotoxic drug according to the FDA regulatory guidelines for analytical procedures (57)
Equation R2 LOD LLOQ Range
5-FU Peak area=35209+16473.8x5-FU 0.9983 0.900 ng 2.728 ng LOD-75 ng
CP Peak area=35230.8+25147.7xCP 0.9936 1.78 µg 5.40 µg LOD-60 µg
PTX Peak area=21507.4+147442xPTX 0.9923 0.20 ng 061 ng LOD-16.65 ng
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Of the total fifty nine samples collected, 45 were 
contaminated with one or more drugs. Considering only the 
results higher than the LOQ, contamination before and 
during drug handling did not differ significantly (p>0.05) 
in any of the three units. However, the units did differ in 
contamination with CP and 5-FU. CP was significantly 
higher in the preparation unit than in other units three hours 
into the drug handling, and significantly higher in the 
administration unit than the others before drug handling 
(Figure 3). In turn, 5-FU was significantly higher in the 
preparation unit and the patient toilet three hours into the 
drug handling, while in the administration unit the 
concentration was higher before (Figure 4). Contamination 
with PTX was not statistically analysed because there were 
too few quantifiable samples to compare.
Table 10 shows the three sampling spots with 
significantly higher contamination with any of the cytotoxic 
drugs compared to the rest.
DISCUSSION
Our results clearly show that the current cleaning 
procedure is ineffective in removing contamination with 
the three representative cytotoxic drugs. They also suggest 
that other variables contributed to contamination as well.
Our findings are similar to the contamination reported 
in Portuguese hospitals (33), but we did not expect to find 
higher contamination in the drug administration unit than 
in the preparation unit, where drugs are handled and mixed 
in high concentrations (33, 34).
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Table 2 HPLC intra-day and inter-day (n=5) quantification accuracy and precision for 5-fluorouracil (injection volume 100 µL)
Nominal amount 
(ng)
Measured amount 
(ng) SD
Precision 
(%RSD)
Accuracy 
(%)
Intra-day
7.500 6.950 0.49 7.10 -7.33
15.000 15.300 0.09 0.60 2.00
30.000 30.840 0.08 0.27 2.80
45.000 44.360 0.89 2.00 -1.42
60.000 60.050 1.23 2.05 0.08
75.000 72.270 1.67 2.31 -3.64
Inter-day
7.500 7.050 0.18 2.56 -6.00
15.000 15.100 0.21 1.41 0.67
30.000 29.840 0.45 1.50 -0.53
45.000 45.380 0.53 1.16 0.84
60.000 58.550 0.24 0.41 -2.42
75.000 76.270 0.28 0.37 1.69
Table 3 HPLC intra-day and inter-day (n=5) quantification accuracy and precision for cyclophosphamide (injection volume 100 µL)
Nominal amount 
(µg)
Measured amount 
(µg) SD
Precision 
(%RSD)
Accuracy 
(%)
Intra-day
6.000 5.300 0.36 6.7 -11.7
12.000 12.300 0.43 3.5 2.5
24.000 25.160 0.55 2.2 4.8
36.000 35.240 0.74 2.1 -2.1
48.000 44.230 0.75 1.7 -7.9
60.000 51.000 1.79 3.5 -15.0
Inter-day
6.000 5.50 0.28 5.14 0.4
12.000 12.02 0.53 4.4 -8.3
24.000 23.70 0.88 3.7 0.2
36.000 36.0 2.20 6.1 -1.3
48.000 48.2 2.31 4.8 0.0
60.000 58.896 3.53 6.0 0.4
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In the preparation unit the most contaminated surfaces 
before drug handling were the ones in the support room and 
three hours into the handling, the most contaminated 
surfaces were the ones in the clean room (Table 7), which 
is quite expected as handling goes. Clean rooms are the 
central points for drug preparation but are also more 
thoroughly cleaned than other rooms when handling is over. 
This probably explains the distribution of contaminated 
surfaces at both sampling times in both units (Figures 2 and 
3 and Table 10). Similar findings were reported by Fleury-
Souverain et al. (30) for samples collected after the handling 
started, as they did not collect samples after cleaning.
In our study, 5-FU was found in most samples at both 
sampling time points, which confirms the findings reported 
by Kiffmeyer et al. (24). They also reported that 5-FU was 
the most used drug, which may explain our findings as well.
In both of our units and the patient toilet the most 
contaminated surfaces were the ones handled without gloves 
(phones, computer mouse, bed in the treatment room, toilet 
light switch, flush handle, and handlebars) regardless of the 
sampling time point. The same was reported in our previous 
study (33), where we attributed contamination to 
inappropriate cleaning and drug handling procedures. The 
same pattern was observed in a study of Italian hospitals 
(41), which reported that workers did not remove gloves 
immediately after drug handling, and therefore spread the 
contamination on phones, chairs, closets and other surfaces 
not directly involved in drug preparation and administration. 
The same conclusions were reported by Kiffmeyer et al. 
(24), who found high concentrations of 5-FU on a closet 
door knob that was not used to store 5-FU.
Contamination of infusion pumps after drug 
administration started is similar to earlier reports (19, 33, 
42). In fact, Hon et al. (34) claim that infusion pumps are 
most often touched by nurses during drug administration. 
This is of particular concern, because we found contamination 
before and after drug administration and also observed that 
the pumps were sometimes handled without gloves. Clearly, 
this equipment is not being cleaned.
We would also like to draw attention to the contamination 
of the beds in the treatment room, bed chart holders in 
particular. We observed that this surface was handled/
touched by nurses and patients' families, implicating 
exposure for all these persons. This is one more surface that 
probably is not being cleaned well or often enough.
Furthermore, a study of health and safety practices by 
nurses that administered cytotoxic drugs in 2011 reported 
that 12 % of the 2069 respondents failed to use gloves, even 
though 4 % reported skin contact with the drug during 
handling and administration (44).
Figure 3 CP contamination (µg cm-2) before and after drug handling started in each unit
Figure 4 5-FU contamination (ng cm-2) before and after drug handling started in each unit
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We also have to draw attention to the widespread 
contamination of the patient toilet before and after drug 
handling started, as it puts family members at risk of 
exposure, making this a public health issue as well. These 
findings raise particular concern, because Moretti et al. (13) 
showed in a recent study that handling cytotoxic drugs, 
even under controlled conditions, involves a considerable 
genotoxic risk (13).
What explains much of the contamination found in our 
study is that our ODS had only a biological safety cabinet, 
located in the clean room, but not a closed-system drug 
transfer device. By default, biological safety cabinets are 
heavily contaminated and are difficult to clean, and so are 
the objects taken out of the cabinet (45). Closed-system 
drug transfer devices serve to prevent transfer of 
contamination from these objects to outside surfaces (4). 
The benefits of closed drug transfer systems have already 
been demonstrated by Sessink et al. (46) and Simon et al. 
(47), but the latter also noted that the device could not 
completely prevent chemical contamination.
Cleaning issues and recommendations
The recent EU recommendations (4) identify cleaning 
as critical in reducing the spread of contamination. Cleaning 
can reduce most of the contamination, but not all of it, 
because there is no universal agent for different chemical 
structures of cytotoxic drugs.
Several authors have tried to find a an agent capable of 
inactivating, degrading, and reducing contamination with 
cytotoxic drugs in oncology services (48-55), but the issue 
remains. Our study only confirms that, as we found 
contamination even on supposedly cleaned surfaces before 
drug handling began.
Assessing the efficacy of the cleaning methods usually 
employed in their healthcare facility to eliminate 
environmental contamination with CP, Touzin et al. (55) 
recommended combining sodium hypochlorite and sodium 
thiosulfate to obtain optimal results. However, this and 
many other studies address decontamination of a single 
cytotoxic agent (48, 55-57), while in reality surfaces are 
often contaminated with several agents. Lamerie et al. (52) 
therefore assessed the efficiency of several chemical 
solutions to decontaminate two types of work surfaces 
intentionally contaminated with ten cytotoxic drugs. 
Sodium hypochlorite showed the highest overall efficiency 
of 98 %. Promising were also solutions containing anionic 
surfactants with a high efficiency to safety ratio, as they 
bind to impurities and particles that are suspended in the 
liquid, which makes them effective cleaning agents in water. 
In fact, the EU report (4) clearly points out that no single 
chemical can completely clean, disinfect, and decontaminate 
surfaces contaminated with cytotoxic drugs.
The cleaning product used in our ODS was the same as 
the ones used in other hospital facilities not handling 
cytotoxic agents. This suggests that there are no set criteria 
to select a cleaning product that would be specific for an 
ODS and effective enough to warrant chemical 
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Table 4 HPLC intra-day and inter-day (n=5) quantification accuracy and precision for paclitaxel (injection volume 100 µL)
Nominal amount 
(ng)
Measured amount 
(ng) SD
Precision 
(%RSD)
Accuracy 
(%)
Intra-day
1.665 1.812 0.395 21.811 8.80
3.330 3.014 0.182 6.035 -9.50
6.660 6.554 0.474 7.230 -1.60
9.990 10.212 0.266 2.601 2.22
13.320 13.800 0.447 3.243 3.60
16.650 16.220 0.448 2.763 -2.58
Inter-day
1.665 1.730 0.07 4.15 3.9
3.330 3.12 0.17 5.35 -6.3
6.660 6.450 0.26 4.1 -3.2
9.990 10.20 0.62 6.1 2.1
13.320 13.700 0.86 6.3 2.9
16.650 16.320 1.15 7.02 -2.0
Table 5 Recovery of the cytotoxic drugs from spiked wipes (n=3)
Drug Nominal amount
Recovery 
(%)
5-FU (ng)
15 95.80
45 86.30
75 91.03
CP (µg)
12 93.43
36 96.55
60 95.32
PTX (ng)
3.33 80.85
9.99 85.37
16.65 87.24
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Table 6 Samples with values >LOQ
Sampling before 
(n=29)
Sampling after 
(n=30)
Drugs CP (µg cm-2)
5-FU 
(ng cm-2)
PTX 
(ng cm-2)
CP 
(µg cm-2)
5-FU 
(ng cm-2)
PTX 
(ng cm-2)
Positive samples 7 16 2 10 20 0
Mean 
Range 
16.5 
LOD – 139.55
17 
LOD - 85.35
0.24 
LOD – 3.67
2.0 
LOD – 93.92
19.0 
LOD - 88.72 <LOQ
Table 7 Surface contamination levels by each drug before handling (n=29)
Unit Surfaces
Drug
Specific 
surfaces
CP 
(µg cm–2)
Specific 
surfaces
5-FU 
(ng cm–2)
PTX 
(ng cm–2)
Pr
ep
ar
at
io
n 
(n
=1
2)
Clean room – biological safety cabinet (BSC)
chair 0 0 1.98
Clean room – pass through handle 0 24.48 0
Clean room – support table 0 0 0
Clean room – front barrier grating of the BSC 0 0 0
Clean room – handle of the BSC protection 0 0 0
Support room – table receiving finished 
preparations 40.18 0 0
Support room – table where preparations done 
are registered 19.83 0 0
Support room – box for manual transportation 0 0 0
Support room – pass through handle and 
interior 0 0 <LOQ
Support room – computer mouse 0 27.18 0
Support room – phone 0 85.35 <LOQ
Support room – drug storage cabinet –  
handles and interior 0 27 0
A
dm
in
is
tr
at
io
n 
(n
=1
2)
Infusion pump holder 58.85 0 0
Pass through handle 97.05 21 0
Table that receives drug preparations 0 0 0
Computer mouse 0 44.4 0
Table for preparing other medication 0 11.93 0
Treatment chairs – armrests 0 <LOQ 0
Trolley worktop 41.32 0 0
Treatment room – bed chart holder, infusion 
pump holder, and chair armrest Bed 139.55
Bed 26.6
0Chair  
armrest 4.28
Nurse desk – phone, desk, chair 0
Phone 84.69
0Table 22.81
Chair 35.67
Pa
tie
nt
s t
oi
le
t 
(n
=5
)
Door handles 0 17 0
Light switch 32.01 25.76 0
Flush handle 0 12.04 3.67
Arm support 0 4.99 0
Water tap 0 0 0
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decontamination of the surfaces. The cleaning product used 
in our ODS contained sodium tripolyphosphate, sulphonic 
acid, sodium lauryl ether sulphate, propan-2-ol, and a small 
percentage of alcohol. The toilet was cleaned with a product 
containing sodium hypochlorite instead. However, despite 
the use of sodium hypochlorite, almost all toilet samples 
showed contamination. This points to other factors that may 
render decontamination less efficient, such as dilution and 
the agent contact time with the surface (55).
However, we also believe the criteria used to select 
which surfaces to clean affected the findings reported by 
this and previous studies. They are focused on rendering 
the surfaces aseptic by removing microorganisms, because 
oncology patients are most often immunocompromised. 
Accordingly, the cleaning solutions are selected based on 
their disinfection efficacy and not on chemical 
decontamination.
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Table 8 Surface contamination level by each drug after the beginning of tasks (n=30)
Unit Surfaces
Drug
CP 
(µg cm–2)
Specific 
surfaces
5-FU 
(ng cm–2)
Specific 
surfaces
PTX 
(ng cm–2)
Pr
ep
ar
at
io
n 
(n
=1
2)
Clean room – biological safety cabinet (BSC) 
chair 93.92 31.75 <LOD
Clean room – pass through handle (sample 1) 18.9
Clean room – pass through handle (sample 2) 71.32 16.6 <LOD
Clean room – support table <LOD <LOD <LOD
Clean room – front barrier grating of the BSC 45.99 <LOD <LOD
Clean room – handle of the BSC protection <LOD 18.8 <LOD
Support room – table receiving finished 
preparations 12.27 <LOD <LOD
Support room – table where preparations 
done are registered <LOD 1.86 <LOD
Support room – Pass through handle and 
interior 2 <LOD <LOD
Support room – computer mouse 12.81 36.49 <LOD
Support room – phone 13.03 23.52 <LOD
Support room – drug storage cabinet –  
handles and interior <LOD Handle 4.61 <LOD
A
dm
in
is
tr
at
io
n 
(n
=1
3)
Infusion pumps holder and pump <LOD Pump 25.21 <LOD
Transfer interior and handle <LOD Handle <LOQ <LOD
Table that receives drug preparations <LOD <LOD <LOD
Computer mouse 13.15 17 <LOD
Table for preparing other type of medication <LOD <LOD <LOD
Treatment chairs – armrests <LOD 2.32 <LOD
Trolley worktop <LOD <LOD <LOD
Catheters room – table 11.98 <LOD 0<LOD
Treatment room – bed chart holder, infusion 
pump holder, and chair armrest <LOD
Bed 12.44
Bed <LOQInfusion 
pump holder 8.85
Nurse desk – phone <LOD
Phone 88.72
Phone <LOQTable 4.33
Chair 10.43
Pa
tie
nt
s t
oi
le
t 
(n
=5
)
Door handles <LOD 21 <LOQ
Light switch <LOD 2.57 <LOD
Flush handle <LOD 19.73 <LOD
Arm support <LOD 70.03 <LOD
Water tap <LOD 73.32 <LOD
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Additionally, mainly the toilet floor was cleaned and 
not the surfaces touched by hand. This explains why all the 
toilet surfaces were contaminated before and after the drug 
handling started at the ODS.
Surface monitoring recommendations
This study stresses the importance of each oncology 
service having an effective monitoring programme in place. 
Monitoring should be frequent and collect reliable and 
detailed exposure information to identify the causes of 
contamination and appropriate measures to avoid or 
minimise exposure. Kiffmeyer et al. (24) reported a 
sustained contamination control thanks to one such regular 
monitoring programme. Furthermore, monitoring can show 
where cleaning has failed. Sampling should precede the 
implementation of preventive measures and be repeated 
once they are in place to establish their efficiency (60). 
Viegas et al. (64) demonstrated the usefulness of surface 
monitoring, as it not only gives an indirect measure of 
dermal exposure but also relevant guidelines to prevent 
further exposure.
Although this study findings call for changes in the 
workflow and cleaning that would reduce contamination 
and exposure to cytotoxic drugs, it has several limitations 
to bear in mind. One is the limited number of positive 
samples for PTX, even though it is the most used cytotoxic 
drug in this ODS. This points to the need to revise the 
sampling method and frequency. The other limitation is that 
we did not sample exactly the same surfaces before and 
three hours into the drug handling because some of the 
surfaces were covered by objects used in everyday 
operations and therefor inaccessible. For this reason we 
cannot reliably follow how contamination developed 
between the two sampling times.
CONCLUSIONS
Our results have shown a widespread contamination in 
the ODS even after it has been cleaned and call for 
improvements to define an optimise cleaning. This includes 
the selection of proper cleaning agents or combinations 
thereof, optimal dilution, and contact time with the surfaces. 
This can only be accomplished in collaboration with trained 
cleaners, who have been made aware of the risks of poor 
cleaning practices.
Operating procedures, including technical resources 
should also be improved to avoid or reduce the spread of 
contamination. A surface monitoring programme could 
greatly contribute to achieve that goal, as it can provide 
guidelines for improvement.
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Profesionalna izloženost citotoksičnim lijekovima: koliko je važno čišćenje površina za njezino sprječavanje 
odnosno smanjenje
U zdravstvenih radnika koji pripremaju ili primjenjuju citotoksične lijekove zdravstveni rizici zbog izloženosti su realni, 
čak i pri dozama nižima od onih koje se primjenjuju u bolesnika jer, načelno, nijedna doza nije neškodljiva za zdravlje. 
Najčešći i najproblematičniji put izlaganja jest koža, napose zato što radne površine gdjekad ostanu kontaminirane i nakon 
njihova čišćenja. Cilj ovoga preliminarnog istraživanja bio je pokazati koliko je važno osmisliti djelotvoran protokol za 
dekontaminaciju na temelju pokazatelja kontaminacije radnih površina jedinice za pripremu lijekova, jedinice za njihovu 
primjenu te bolesničkoga zahoda onkološke ambulante trima najčešćim citotoksičnim onkološkim lijekovima: 
ciklofosfamidom, 5-fluoroacilom i paklitakselom. Uzorke smo prikupljali prije rada s lijekovima te tri sata od početka 
rada s njima te ih analizirali tekućinskom kromatografijom s detektorom s nizom dioda (engl. high performance liquid 
chromatography with diode array detection, krat. HPLC-DAD). Od 29 uzoraka prikupljenih prije rada s lijekovima, 23 
su bila kontaminirana, od kojih pet s više lijekova. Od 30 uzoraka prikupljenih tri sata nakon početka rada s lijekovima, 
njih 25 bilo je kontaminirano, od kojih osam s više lijekova. Kontaminacija površina prije i nakon početka rada s lijekovima 
nije bila značajno različita, što upozorava na raširenu kontaminaciju i nedjelotvorno čišćenje. Stoga bi trebalo revidirati 
postojeći protokol čišćenja i rukovanja lijekovima te svesti kontaminaciju na najmanju moguću mjeru.
KLJUČNE RIJEČI: 5-fluoroacil; ciklofosfamid; HPLC-DAD; onkološka ambulanta; paklitaksel; suzbijanje kontaminacije
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